{"id":40892,"date":"2025-09-08T15:18:43","date_gmt":"2025-09-08T07:18:43","guid":{"rendered":"https:\/\/flcube.com\/?p=40892"},"modified":"2025-09-08T15:18:43","modified_gmt":"2025-09-08T07:18:43","slug":"innocare-pharma-secures-singapore-hsa-approval-for-orelabrutinib-in-relapsed-mzl","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40892","title":{"rendered":"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL"},"content":{"rendered":"\n<p><strong>Shanghai\u2011based InnoCare Pharma (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688428:SHA\">SHA: 688428<\/a>)<\/strong> announced on <strong>September\u202f8,\u202f2025<\/strong> that its Bruton&#8217;s tyrosine kinase (BTK) inhibitor <strong>Orelabrutinib<\/strong>\u2014marketed in Singapore as <strong>Ino\u201103<\/strong>\u2014has received <strong>Health Sciences Authority (HSA)<\/strong> clearance for the treatment of <strong>adult patients with relapsed\/refractory marginal zone lymphoma (R\/R\u202fMZL)<\/strong>.<br>This marks the drug\u2019s <strong>second approved indication in Singapore<\/strong>; the first, granted in November\u202f2022, covered <strong>relapsed\/refractory mantle cell lymphoma (R\/R\u202fMCL)<\/strong>.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Highly selective BTK inhibition with minimal off\u2011target activity.<\/li>\n\n\n\n<li><strong>Safety Advantage<\/strong> \u2013 Designed to reduce adverse events common to earlier BTK inhibitors.<\/li>\n\n\n\n<li><strong>Therapeutic Scope<\/strong> \u2013 Approved in China for CLL\/SLL, MCL, MZL, and first\u2011line CLL\/SLL (April\u202f2025).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Singapore<\/strong> \u2013 HSA approval extends Orelabrutinib\u2019s reach to a new lymphoma subtype, strengthening its market presence in the region.<\/li>\n\n\n\n<li><strong>China<\/strong> \u2013 Orelabrutinib\u2019s regulatory journey began in December\u202f2020 (CLL\/SLL &amp; MCL) and has since expanded to MZL (April\u202f2023) and first\u2011line CLL\/SLL (April\u202f2025).<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-clinical-landscape\">Clinical Landscape<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>R\/R MZL<\/strong> \u2013 Limited approved options; Orelabrutinib offers a targeted alternative with a favorable safety profile.<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong> \u2013 The drug\u2019s selectivity differentiates it from other BTK inhibitors that carry higher toxicity risks.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion<\/strong> \u2013 The dual Singapore approvals position InnoCare to capture a broader patient base across the Asia\u2011Pacific.<\/li>\n\n\n\n<li><strong>Pipeline Synergy<\/strong> \u2013 Success in MZL may accelerate development of Orelabrutinib in other hematologic malignancies and autoimmune indications.<\/li>\n\n\n\n<li><strong>Investor Outlook<\/strong> \u2013 The approvals are expected to bolster InnoCare\u2019s valuation by unlocking new revenue streams and enhancing its competitive moat.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai\u2011based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September\u202f8,\u202f2025 that its Bruton&#8217;s tyrosine kinase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40893,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,919,327,15,920,33],"class_list":["post-40892","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-9969","tag-innocare-pharma","tag-product-approvals","tag-sha-688428","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai\u2011based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September\u202f8,\u202f2025 that its Bruton&#039;s tyrosine kinase (BTK) inhibitor Orelabrutinib\u2014marketed in Singapore as Ino\u201103\u2014has received Health Sciences Authority (HSA) clearance for the treatment of adult patients with relapsed\/refractory marginal zone lymphoma (R\/R\u202fMZL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40892\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL\" \/>\n<meta property=\"og:description\" content=\"Shanghai\u2011based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September\u202f8,\u202f2025 that its Bruton&#039;s tyrosine kinase (BTK) inhibitor Orelabrutinib\u2014marketed in Singapore as Ino\u201103\u2014has received Health Sciences Authority (HSA) clearance for the treatment of adult patients with relapsed\/refractory marginal zone lymphoma (R\/R\u202fMZL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40892\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-08T07:18:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0808.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL\",\"datePublished\":\"2025-09-08T07:18:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892\"},\"wordCount\":263,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0808.webp\",\"keywords\":[\"Cancer\",\"HKG: 9969\",\"InnoCare Pharma\",\"Product approvals\",\"SHA: 688428\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40892#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40892\",\"name\":\"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0808.webp\",\"datePublished\":\"2025-09-08T07:18:43+00:00\",\"description\":\"Shanghai\u2011based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September\u202f8,\u202f2025 that its Bruton's tyrosine kinase (BTK) inhibitor Orelabrutinib\u2014marketed in Singapore as Ino\u201103\u2014has received Health Sciences Authority (HSA) clearance for the treatment of adult patients with relapsed\\\/refractory marginal zone lymphoma (R\\\/R\u202fMZL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40892\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0808.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0808.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40892#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai\u2011based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September\u202f8,\u202f2025 that its Bruton's tyrosine kinase (BTK) inhibitor Orelabrutinib\u2014marketed in Singapore as Ino\u201103\u2014has received Health Sciences Authority (HSA) clearance for the treatment of adult patients with relapsed\/refractory marginal zone lymphoma (R\/R\u202fMZL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40892","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL","og_description":"Shanghai\u2011based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September\u202f8,\u202f2025 that its Bruton's tyrosine kinase (BTK) inhibitor Orelabrutinib\u2014marketed in Singapore as Ino\u201103\u2014has received Health Sciences Authority (HSA) clearance for the treatment of adult patients with relapsed\/refractory marginal zone lymphoma (R\/R\u202fMZL).","og_url":"https:\/\/flcube.com\/?p=40892","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-08T07:18:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0808.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40892#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40892"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL","datePublished":"2025-09-08T07:18:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40892"},"wordCount":263,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40892#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0808.webp","keywords":["Cancer","HKG: 9969","InnoCare Pharma","Product approvals","SHA: 688428","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40892#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40892","url":"https:\/\/flcube.com\/?p=40892","name":"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40892#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40892#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0808.webp","datePublished":"2025-09-08T07:18:43+00:00","description":"Shanghai\u2011based InnoCare Pharma (HKG: 9969, SHA: 688428) announced on September\u202f8,\u202f2025 that its Bruton's tyrosine kinase (BTK) inhibitor Orelabrutinib\u2014marketed in Singapore as Ino\u201103\u2014has received Health Sciences Authority (HSA) clearance for the treatment of adult patients with relapsed\/refractory marginal zone lymphoma (R\/R\u202fMZL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40892#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40892"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40892#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0808.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0808.webp","width":1080,"height":608,"caption":"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40892#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma Secures Singapore HSA Approval for Orelabrutinib in Relapsed MZL"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0808.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40892"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40892\/revisions"}],"predecessor-version":[{"id":40894,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40892\/revisions\/40894"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40893"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}